The group of patients with Guillain‐Barré syndrome (GBS) is very heterogenous with regard
to antecedent infections, immunological parameters, clinical manifestations, and response to …

Abstract Objective Intravenous immunoglobulin (IVIg) is the first choice treatment for Guillain‐
Barré syndrome (GBS). All patients initially receive the same arbitrary dose of 2g per kg …

Objective: The aim of the study was to determine whether Guillain-Barré syndrome (GBS) is
associated with preceding hepatitis E virus infection. Methods: The frequency of hepatitis E …

Background and Objectives Infections play a key role in the development of Guillain-Barré
syndrome (GBS) and have been associated with specific clinical features and disease …

The Inflammatory Neuropathy and Treatment (INCAT) group developed a standardized
ELISA method for the detection of serum anti-GM1 antibodies. The diagnostic value of anti …

Objective Guillain‐Barré syndrome (GBS) is an acute postinfectious immune‐mediated
polyneuropathy. Although preceding respiratory tract infections with Mycoplasma …

Background Campylobacter jejuni is the predominant antecedent infection in Guillain-Barré
syndrome (GBS). Molecular mimicry and cross-reactive immune responses to C. jejuni lipo …

Background: Detection of serum antibodies to myelin-associated glycoprotein (MAG) by
Western blot (WB) is a valuable assay to diagnose a distinct type of demyelinating …

Importance There is an urgent need for biomarkers to monitor treatment efficacy and
anticipate outcome in patients with Guillain-Barré syndrome (GBS). Objective To assess …

Intravenous immunoglobulin (IVIg) is the treatment of choice for Guillain–Barré syndrome
(GBS), an immune-mediated peripheral neuropathy causing rapidly progressive limb …